Physician profile
James T Halla
NPI 1497721393
$1,705.30
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,705.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $218.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $205.47 | 2019 | |
| Abbvie INC. | $199.46 | 2019 | |
| Amgen INC. | $173.07 | 2019 | |
| Pfizer INC. | $150.90 | 2019 | |
| Janssen Biotech, INC. | $129.49 | 2019 | |
| Zyla Life Sciences, INC. | $114.37 | 2019 | |
| Celgene Corporation | $105.25 | 2019 | |
| Glaxosmithkline, LLC. | $86.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $57.56 | 2019 | |
| Ucb, INC. | $53.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.81 | 2019 | |
| Genzyme Corporation | $22.49 | 2019 | |
| Fidia Pharma USA INC. | $21.69 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.27 | 2019 | |
| Horizon Therapeutics Plc | $16.13 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.99 | 2019 | |
| Hikma Pharmaceuticals USA | $14.99 | 2019 | |
| Medexus Pharma, INC. | $14.25 | 2019 | |
| Lilly USA, LLC | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Halla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.